Compounded tirzepatide dose visuals: what the syringe math misses

What did @risinghealthreport actually say?

The creator walked through a visual comparison of three compounded tirzepatide doses, specifically 2.5mg, 5mg, and 7.5mg, from Empower Pharmacy. They explained the unit-to-volume conversion: "1cc per mil equals 100 units," and translated each dose into both units and cubic centimeters. They also flagged that concentrations shift above 7.5mg, stating pharmacies will "sprinkle more tirzepatide powder in the same amount of volume" to keep injection volume manageable. The video closed with a reasonable disclaimer: follow your label, ask your provider, and don't assume other people's doses apply to you because "different concentrations."

This is a dose visualization video, not a clinical guide. That framing matters for evaluating what follows.

Does the science back this up?

The unit conversion math is correct, and the concentration-shift concept is real. Compounded medications are not standardized across pharmacies, and this is a documented regulatory concern, not just a TikTok talking point.

The FDA has repeatedly flagged compounded GLP-1 preparations for inconsistent potency and labeling. A 2024 FDA statement on compounded semaglutide and tirzepatide noted that dosing errors are a primary safety risk, largely because patients receive preparations at varying concentrations without standardized labeling. The creator's conversion, 2.5mg equals 31 units at this specific concentration, is consistent with a roughly 8mg/mL concentration, which aligns with Empower Pharmacy's publicly available formulation data as of early 2024. The 5mg dose math (63 units) suggests slight rounding, as a strict calculation at 8mg/mL would yield 62.5 units. Not a meaningful clinical error, but worth noting.

The point about higher doses being compounded at greater concentrations is also accurate. This is standard compounding practice to avoid large-volume subcutaneous injections, which carry their own tolerability issues.

What did they get wrong (or right)?

Mostly right, with a few rough edges worth flagging. The creator got the core principle correct: compounded tirzepatide concentrations vary by pharmacy, and dose visualization in units is only useful if you know your specific concentration. That is genuinely useful consumer information that is often buried in fine print.

The rounding on the 5mg dose, described as "63 units or 0.61ccs," is slightly inconsistent. At 63 units that would be 0.63cc, not 0.61cc. Small discrepancy, but in a video explicitly about precision dosing, it is the kind of slip that can confuse patients who are trying to self-verify their syringe fill. The creator also uses the phrase "intraceptide" (likely a verbal slip for tirzepatide), which is minor but could confuse newer patients unfamiliar with the drug name.

More importantly, the video never mentions that compounded tirzepatide is not FDA-approved and is not equivalent to brand-name Zepbound or Mounjaro. That omission is not a small thing. The FDA has issued warnings about compounded GLP-1 drugs containing tirzepatide salt forms (specifically tirzepatide acetate and tirzepatide trifluoroacetate) rather than the base compound used in approved products. These are not the same molecule in clinical terms, and patients deserve to know that before interpreting syringe volumes.

What should you actually know?

Your syringe math only works for your specific pharmacy and your specific formulation. This cannot be repeated enough. Using someone else's unit conversion, even from a video with 400K views, is a dosing error waiting to happen.

The FDA placed compounded semaglutide and tirzepatide on its shortage list, which temporarily allowed compounding. That status has shifted, and as of 2025, the FDA declared the tirzepatide shortage resolved, meaning many compounding pharmacies may no longer legally produce copies of the branded formulation. Whether a specific pharmacy is operating within current regulatory bounds is something your prescribing provider needs to verify, not a TikTok creator. The creator's closing advice, "follow what's on your label, ask your provider, reach out and confirm" is genuinely the right call. That part deserves credit. But that advice needs more weight than a closing line in a dose visualization video. It is the entire point.

• Always verify your concentration with your dispensing pharmacy before drawing any dose.
• If your label and your syringe math do not match, call the pharmacy before injecting.
• Compounded tirzepatide is not interchangeable with Zepbound or Mounjaro, legally or clinically.

Bottom line

This video is more responsible than most GLP-1 content on TikTok. The creator knows the material, flags the pharmacy-to-pharmacy variation appropriately, and does not tell viewers to copy their doses. The math has a small inconsistency, the lack of any mention of FDA approval status is a real omission, and the visual format could genuinely help patients understand their syringes. Take the concept, verify every number with your own pharmacist, and do not skip the conversation with your provider.